Original language | English |
---|---|
Pages (from-to) | 409-410 |
Number of pages | 2 |
Journal | Science |
Volume | 362 |
Issue number | 6413 |
DOIs | |
State | Published - 26 Oct 2018 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Science, Vol. 362, No. 6413, 26.10.2018, p. 409-410.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Protect NIH's DNA advisory committee
AU - Adelman, Zach N.
AU - Albritton, Lorraine M.
AU - Boris-Lawrie, Kathleen
AU - Buchmeier, Michael J.
AU - Cannon, Paula
AU - Cho, Mildred
AU - DiGiusto, David
AU - Donahue, J. Kevin
AU - Federoff, Howard J.
AU - Hammarskjold, Marie Louise
AU - Hardison, Angelica D.
AU - Hearing, Patrick
AU - Lee, Benhur
AU - Lee, Dean Anthony
AU - Porteus, Matthew H.
AU - Ross, Lainie Friedman
AU - Ross, Susan R.
AU - Wooley, Dawn P.
AU - Zoloth, Laurie
N1 - Funding Information: The Recombinant DNA Advisory Committee (RAC) was founded at the behest of concerned scientists based on the principle that public trust of advanced technologies must be earned through transparency and expert deliberation. For more than 40 years, the RAC has served as custodian of the National Institutes of Health (NIH) guidelines, with responsibilities in human gene therapy evolving from regulatory to advisory to the NIH and Food and Drug Administration (FDA). However, the NIH director and FDA commissioner have proposed the elimination of RAC review of human gene therapy protocols (1, 2).
PY - 2018/10/26
Y1 - 2018/10/26
UR - http://www.scopus.com/inward/record.url?scp=85055616683&partnerID=8YFLogxK
U2 - 10.1126/science.aav2483
DO - 10.1126/science.aav2483
M3 - Letter
C2 - 30361364
AN - SCOPUS:85055616683
SN - 0036-8075
VL - 362
SP - 409
EP - 410
JO - Science
JF - Science
IS - 6413
ER -